



March 14, 2024

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

Notice of Conclusion of License Agreement and Revision of Consolidated Financial Results Forecast for the Fiscal Year Ending December 31, 2024

AnGes Inc. announces that EmendoBio Inc. and Anocca AB (Forskargatan 20 C 151 36 Södertälje, Sweden: Representative: Reagan Jarvis, CEO, Scientific founder, hereinafter referred to as "Anocca") have decided to conclude a license agreement.

1. Summary of License Agreement

EmendoBio has decided to grant Anocca a non-exclusive license to use its proprietary OMNI-A4 nuclease, which avoids the "off-target effect" that is a challenge in genome editing.

Anocca will use EmendoBio's proprietary OMNI-A4 nuclease to develop TCR-T cell therapies targeting mutations in the KRAS protein, which is involved in cell growth in solid tumors.

The agreement is a non-exclusive license agreement, and while EmendoBio will have the freedom to conduct licensing activities in the future, it is expected to receive upfront payment, development milestone and other revenues, which together with the upfront payment of 500,000 USD and development milestone could total up to approximately 100 million USD (14.5 billion yen, based on 145 yen/1USD). In addition, they may receive royalties if their products are sold.

Please refer to the attached press release for details regarding this agreement.

2. Outline of Contract Partner

Company Name	Anocca AB
Location	Forskargatan 20C 151 36 Södertälje, Sweden
Title and name of representative	Reagan Jarvis CEO, Scientific founder
Business	Biotechnology
Establishment	2014

3. Future Outlook

As an upfront payment will be recorded in the second quarter of the current fiscal year in connection with this contract, we have revised our consolidated earnings forecast for the fiscal year ending December 31, 2024, as follows.

Forecast for FY2024

	Revenues	Operating Profit	Ordinary Profit	Profit	Profit/Share
Previous Forecast	530	-8,500	-8,500	-8,700	-43.84
Revised Forecast	600	-8,450	-8,450	-8,650	-43.58
Increase/Decrease	70	50	50	50	0.26
Percentage change	13.2%	—	—	—	—
FY2023	152	-11,967	-5,651	-7,437	-39.29

(Note) This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.

Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.

Enabling Technology Supports the Development of Anocca's Deep Pipeline of TCR-T therapeutics

New York, USA, & Södertälje, Sweden, 14th March 2024 –Anocca AB (Anocca), a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, and EmendoBio Inc. (EmendoBio), a nuclease discovery and gene editing therapeutics company, today announced a non-exclusive licensing agreement for the use of EmendoBio's novel OMNI-A4 nuclease to accelerate the manufacture and development of Anocca's deep pipeline of TCR-T cell therapies for difficult-to-treat solid cancers.

“Integrating EmendoBio's nuclease into our manufacturing process supports Anocca's aim of generating the highest-quality cell therapy products. This next-generation gene editing system provides the precision and efficiency needed to scale out production of our growing libraries of TCR-T products in a high-precision manufacturing process. We are excited to work with EmendoBio to develop gene-edited TCR-T cell therapies as we prepare for our first clinical program targeting the KRAS driver mutation in a hard-to-treat solid cancer” said Anocca's CEO and co-founder, Reagan Jarvis.

“This non-exclusive licensing agreement marks a significant milestone in the field of T-cell therapy,” said Dr. Ei Yamada, Director of EmendoBio. “Together with Anocca, we are embracing the shared vision of harnessing the potential of gene editing and cellular therapies to make a profound impact on patient outcomes. Our combined expertise will unlock novel avenues for therapeutic development and push the boundaries of what's possible in advanced medicine.”

Anocca recently received certification of GMP compliance and a manufacturing license from the Swedish regulators for their cell therapy production facility, the largest in the Nordics. EmendoBio's technology strengthens Anocca's manufacturing capability and provides a foundation for the ambitious goal of reaching more patients faster with personalised treatments targeting the underlying genetic drivers of hard-to-treat cancers. The licensed gene editing technology is part of EmendoBio's portfolio of proprietary nucleases developed to be highly active and specific for cell therapy applications.

Anocca's and Emendo's commitment to innovation and scientific excellence sets the stage for a promising future in T cell therapies. The agreement not only underscores the significance of collaborative efforts in the biotechnology sector but also reinforces both companies' dedication to improving global healthcare outcomes.

(Note) This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.

Notes to editors

About EmendoBio

EmendoBio is a next-generation CRISPR gene editing company leveraging its proprietary technology to enable high precision gene editing, which is critical for the development of safe medical applications of genome editing. Driven by cutting-edge computational biology, novel gene editing strategies, and the latest of protein engineering tools, EmendoBio's novel nuclease discovery platform, OMNI, broadens the targetable range of the genome, while its target-specific optimization platform enables highly precise editing that maintains high efficiencies.

EmendoBio's proprietary OMNI nucleases also are designed to reduce "off-target" effects, i.e., cleavage at locations other than the targeted genes. Achieving such pinpoint precision is a substantial challenge for genome editing therapies.

The capabilities of the OMNI technology platform, along with deep expertise in genomic medicine and protein engineering, provide EmendoBio with a unique advantage when addressing indications, including within haematology, cardiovascular, ophthalmology, oncology, and other disease areas.

About Anocca

Anocca is a fully integrated biopharmaceutical company developing libraries of T cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours. Its proprietary technologies have been designed to vastly expand TCR-T development, allowing the systematic generation of treatments for the broadest patient populations that equip the immune system against the most difficult to treat solid cancers.

Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem and in-house clinical manufacturing and process development facilities. Its unique discovery platform uses programmable human cells to recreate and manipulate T cell immunity.

Follow Anocca on [LinkedIn](#) and visit www.anocca.com.

Media Inquiries

Anocca AB

Mark Farmery, CDO

media@anocca.com

(Note) This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.

Press Release

Scius Communications (for Anocca AB)

Katja Stout

Tel: +44 7789 435 990

katja@sciuscommunications.com

Daniel Gooch

Tel: +44 7747 875 479

daniel@sciuscommunications.com

EmendoBio Inc.

Naoya Satoh, CEO

nsato@emendobio.com

Noa Wertheimer

Tel: +972 54 6437741

noaw@emendobio.com

(Note) This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.